Will DEA Wind The PDUFA Clock? Scheduled Drugs May Get Complete Response Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai sues FDA seeking longer NCE exclusivity for Fycompa and Belviq.
You may also be interested in...
NCE Market Exclusivity: Eisai Targets DEA Scheduling Delays, Pozen Pushes Bill For Combo Products
Eisai citizen petition requests Belviq and Fycompa approval dates coincide with final DEA scheduling; Pozen advocates exclusivity for new combinations of previously approved molecules.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.